SCHEMBL24258077

SCHEMBL24258077

O=C(O)c1cccc(-c2noc(Cc3ccc(Cl)c(Cl)c3)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.55
NPC1 O15118 5/20 0.55
L3MBTL1 Q9Y468 4/20 0.55
TDP1 Q9NUW8 5/20 0.53
MAPK1 P28482 4/20 0.53
TSHR P16473 3/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.50
ERCC1 P07992 1/20 0.48
ERCC4 Q92889 1/20 0.48
FFAR1 O14842 5/20 0.47
MAOA P21397 1/20 0.47
BLVRB P30043 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
S1PR3 Q99500 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
GAA P10253 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26004984 0.90 RAB9A (0.55) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL59565 0.88 RAB9A (0.68) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL60707 0.85 RAB9A (0.67) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL26004943 0.85 MAPK1 (0.67) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL60059 0.83 RAB9A (0.55) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL59629 0.81 SMN1; SMN2 (0.72) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL28953168 0.80 NPC1 (0.61) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL29800132 0.80 NPC1 (0.61) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL25299060 0.77 NPC1 (0.58) RAB9ANPC1L3MBTL1TDP1MAPK1
SCHEMBL31362818 0.77 NPC1 (0.58) RAB9ANPC1L3MBTL1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 RAB9A 1589/4885NPC1 887/4885L3MBTL1 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.